Ivan M Borrello

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Cancer vaccines for hematologic malignancies
    Ivan M Borrello
    Department of Oncology at the Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Control 9:138-51. 2002
  2. ncbi request reprint Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens
    Alex Cuenca
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 63:9007-15. 2003
  3. pmc Can we change the disease biology of multiple myeloma?
    Ivan Borrello
    The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Leuk Res 36:S3-12. 2012
  4. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
  5. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
  6. pmc Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
    Ivan M Borrello
    The Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 114:1736-45. 2009

Research Grants

Detail Information

Publications6

  1. ncbi request reprint Cancer vaccines for hematologic malignancies
    Ivan M Borrello
    Department of Oncology at the Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Control 9:138-51. 2002
    ..Due to their unique characteristics, hematologic malignancies represent an ideal target for vaccine-based therapeutic interventions...
  2. ncbi request reprint Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens
    Alex Cuenca
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 63:9007-15. 2003
    ....
  3. pmc Can we change the disease biology of multiple myeloma?
    Ivan Borrello
    The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Leuk Res 36:S3-12. 2012
    ....
  4. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  5. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  6. pmc Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
    Ivan M Borrello
    The Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 114:1736-45. 2009
    ..In conclusion, immunotherapy in combination with primed lymphocytes and autologous stem cell transplantation shows encouraging signals of potential activity in acute myeloid leukemia (ClinicalTrials.gov: NCT00116467)...

Research Grants1

  1. The role of myeloid suppressor cells in tumor-specific tolerance
    Ivan M Borrello; Fiscal Year: 2010
    ..Lastly, we will attempt to develop strategies to reduce MSC function in the transplant setting through the use of Viagra and related drugs based on our recent observations that these drugs can effectively inhibit MSC function. ..